Who Paid My Doc
Zokinvy
Drug Cardiovascular
NDC 73079-050-30
General payments
$430,130
Research payments
$1,533,293
Through program year 2023, $430,130 in general payments and $1,533,293 in research payments were reported against Zokinvy (Cardiovascular).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $242,018 | 20 |
| 2023 | Research | $332 | 3 |
| 2022 | General | $88,057 | 13 |
| 2022 | Research | $13,372 | 8 |
| 2021 | General | $100,055 | 9 |
| 2021 | Research | $1,519,589 | 30 |
Breakdown
The top 5 of 8 recipients; each share is of general payments naming this product in 2023.
Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 6 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
42 general · 41 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.